MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Solid Tumors|ER/PR Positive Breast Cancer|Triple Negative Breast Cancer|Metastatic Breast Cancer With Active Brain Metastasis
Interventions: DRUG: Ferumoxytol|DRUG: MM-398
Sponsor: Ipsen